NEWTON, Mass.–(BUSINESS WIRE)–InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a €20 million round of equity financing. Founded in 2015 by Giovanni Righini, a 30-year veteran of the heart valve industry, the company maintains offices […]
Other News
First hospitals in U.S. implant next-generation cardiac device to reduce risk of stroke
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Los Robles Health System perform near simultaneous implantation of WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) AUSTIN, Texas, Aug. 7, 2020 /PRNewswire/ — On Aug. 5, 2020, physicians at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, Texas, and Los Robles Health System in Thousand Oaks, California, became […]
Surmodics Receives FDA 510(k) Clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter
Device designed to treat below-the-knee vessels from the radial arteries with industry’s longest (250 cm) working length EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance […]
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
Study to Explore JAN101’s Potential to Treat Ischemia¹ and Endothelial dysfunction² in COVID-19 patients. LAS VEGAS, Aug. 6, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a […]
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates, clinical impact and outcomes, especially with severe acute respiratory syndrome coronavirus 2 […]
Neovasc Announces Second Quarter Financial Results
VANCOUVER and MINNEAPOLIS, MN, Aug. 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended […]
Cytokinetics Reports Second Quarter 2020 Financial Results
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capital to Support Commercial Development and Pipeline Expansion; Company Expects to End 2020 With More Than $500 Million Cash SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]
iRhythm Technologies Announces Second Quarter 2020 Financial Results
SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2020. Second Quarter 2020 Summary Revenue of $50.9 million – 3% decrease […]
AtriCure Announces Angie Wirick as Chief Financial Officer
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie […]
Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales
– Acceleron expects to report approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – – Acceleron will report its full second quarter 2020 financial and operating results after the close of U.S. financial […]



